EE200300269A - Fibroblasti kasvufaktorid - Google Patents

Fibroblasti kasvufaktorid

Info

Publication number
EE200300269A
EE200300269A EEP200300269A EEP200300269A EE200300269A EE 200300269 A EE200300269 A EE 200300269A EE P200300269 A EEP200300269 A EE P200300269A EE P200300269 A EEP200300269 A EE P200300269A EE 200300269 A EE200300269 A EE 200300269A
Authority
EE
Estonia
Prior art keywords
growth factors
fibroblast growth
fibroblast
factors
growth
Prior art date
Application number
EEP200300269A
Other languages
English (en)
Estonian (et)
Inventor
W. Bringmann Peter
Faulds Daryl
Mitrovic Branislava
Srinivasan Subha
Onuffer James
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of EE200300269A publication Critical patent/EE200300269A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200300269A 2000-12-08 2001-12-10 Fibroblasti kasvufaktorid EE200300269A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25183700P 2000-12-08 2000-12-08
US10/005,646 US20020151496A1 (en) 2000-12-08 2001-12-07 Novel fibroblast growth factors
PCT/US2001/047350 WO2002046424A2 (en) 2000-12-08 2001-12-10 Fibroblast growth factors

Publications (1)

Publication Number Publication Date
EE200300269A true EE200300269A (et) 2003-10-15

Family

ID=26674594

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300269A EE200300269A (et) 2000-12-08 2001-12-10 Fibroblasti kasvufaktorid

Country Status (21)

Country Link
US (2) US20020151496A1 (cg-RX-API-DMAC7.html)
EP (1) EP1389237A2 (cg-RX-API-DMAC7.html)
JP (1) JP2005506275A (cg-RX-API-DMAC7.html)
KR (1) KR20040052442A (cg-RX-API-DMAC7.html)
CN (1) CN1518597A (cg-RX-API-DMAC7.html)
AU (1) AU2603402A (cg-RX-API-DMAC7.html)
BG (1) BG107888A (cg-RX-API-DMAC7.html)
BR (1) BR0116507A (cg-RX-API-DMAC7.html)
CA (1) CA2431374A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20031570A3 (cg-RX-API-DMAC7.html)
EE (1) EE200300269A (cg-RX-API-DMAC7.html)
HU (1) HUP0400657A1 (cg-RX-API-DMAC7.html)
IL (1) IL156259A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03005142A (cg-RX-API-DMAC7.html)
NO (1) NO20032573L (cg-RX-API-DMAC7.html)
PL (1) PL366158A1 (cg-RX-API-DMAC7.html)
RU (1) RU2329058C2 (cg-RX-API-DMAC7.html)
SI (1) SI21372A (cg-RX-API-DMAC7.html)
SK (1) SK7012003A3 (cg-RX-API-DMAC7.html)
WO (1) WO2002046424A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200305236B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
WO2003059270A2 (en) * 2002-01-15 2003-07-24 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
EP1608411B1 (en) * 2003-04-01 2010-09-29 United States Government as represented by the Department of Veteran's Affaires Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure.
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders
LT2726511T (lt) 2011-07-01 2019-11-11 Ngm Biopharmaceuticals Inc Kompozicijos, panaudojimai ir būdai, skirti metabolinių sutrikimų ir ligų gydymui
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
AU2013352363B2 (en) 2012-11-28 2018-04-12 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
AU2013370404B2 (en) 2012-12-27 2017-11-02 Ngm Biopharmaceuticals, Inc. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX377380B (es) 2013-10-28 2025-03-10 Ngm Biopharmaceuticals Inc Modelos de cáncer y métodos asociados.
SI3097122T1 (sl) 2014-01-24 2020-07-31 Ngm Biopharmaceuticals, Inc. Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
UA123763C2 (uk) 2014-10-23 2021-06-02 Енджіем Байофармасьютикалз, Інк. Фармацевтична композиція для контролю або лікування захворювання або порушення, пов’язаного з fgf19
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN107050428B (zh) * 2017-03-23 2020-05-05 温州医科大学 Fgf20药物及其对脑创伤的治疗应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
WO2000060085A1 (en) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
JP2003512841A (ja) * 1999-10-22 2003-04-08 カイロン コーポレイション ヒトおよびラットｆｇｆ−２０遺伝子および遺伝子発現産物
JP2003516731A (ja) * 1999-11-18 2003-05-20 カイロン コーポレイション ヒトｆｇｆ−２１遺伝子および遺伝子発現産物
AU2001262934A1 (en) * 2000-06-01 2001-12-11 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
WO2002002625A2 (en) * 2000-07-03 2002-01-10 Curagen Corporation Novel fibroblast growth factors and nucleic acids encoding same

Also Published As

Publication number Publication date
JP2005506275A (ja) 2005-03-03
CA2431374A1 (en) 2002-06-13
HUP0400657A1 (en) 2006-04-28
US20080057076A1 (en) 2008-03-06
ZA200305236B (en) 2005-06-29
SI21372A (sl) 2004-06-30
EP1389237A2 (en) 2004-02-18
RU2003119657A (ru) 2005-02-27
AU2002226034A2 (en) 2002-06-18
IL156259A0 (en) 2004-01-04
BR0116507A (pt) 2004-01-06
NO20032573D0 (no) 2003-06-06
RU2329058C2 (ru) 2008-07-20
CN1518597A (zh) 2004-08-04
CZ20031570A3 (cs) 2004-01-14
KR20040052442A (ko) 2004-06-23
BG107888A (bg) 2004-08-31
AU2603402A (en) 2002-06-18
US20020151496A1 (en) 2002-10-17
NO20032573L (no) 2003-07-22
WO2002046424A3 (en) 2003-11-27
PL366158A1 (en) 2005-01-24
MXPA03005142A (es) 2004-10-15
SK7012003A3 (en) 2004-04-06
WO2002046424A2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
EE200300269A (et) Fibroblasti kasvufaktorid
DK1333853T3 (da) Vækstfaktorkompleks
NO20024890D0 (no) Implantat
DK1344773T3 (da) Væksthormonsekretionsfremmere
EE05197B1 (et) Linesoliid - kristallivorm II
DE60131102D1 (de) Monofilamentband
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
DE60030011D1 (de) Umpflanzungsmaschine
FR2806309B1 (fr) Implant
AR027931A1 (es) Antitranspirantes
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
CU23064A3 (es) Conjunto implante dental-transportador
AR027982A1 (es) Aril- y heteroarilsulfonatos
FR2803509B1 (fr) Prothese metatarso-phalangienne
AT500246B8 (de) Chokerring
FR2817889B1 (fr) Coffrage
DE60133669D1 (de) Insulinähnlichen wachstumsfaktors 1
ATA12252000A (de) Regensinkkasten
ATA17542000A (de) Hydraulikzylinder
ATA11602000A (de) Sonnenstandsnachführungssystem
ATA19392000A (de) Kippflügelflugzeug
DK1217967T3 (da) Implantat
FI20001470L (fi) Kasvuallas
DK1246934T3 (da) Mikrobielle vækstvariationer
DE60140152D1 (de) Dispergiermittel